Getinge
This information is aimed exclusively at healthcare professionals or other professional audiences and is for informational purposes only, is not exhaustive and therefore should not be relied upon as a replacement of the Instructions for Use, service manual or medical advice. Getinge shall bear no responsibility or liability for any action or omission of any party based upon this material, and reliance is solely at the user’s risk.
Any therapy, solution or product mentioned might not be available or allowed in your country. Information may not be copied or used, in whole or in part, without written permission by Getinge. Views, opinions, and assertions expressed are strictly those of the interviewed and do not necessarily reflect or represent the views of Getinge.
HFSA 2023 - Navigating MCS Selection Amidst the RCT Evidence Gap.
Welcome to the fourth presentation within the session, "HFSA 2023: Reviving Hearts Renewing Lives: The Evolution of Counterpulsation in Heart Failure," from the 2023 Heart Failure Society of America Annual Scientific Meeting.
Navigating MCS Selection Amidst the RCT Evidence Gap.
David A. Baran, MD, FACC, FSCAI, FHFSA, Cleveland Clinic, Weston, FL.
This engaging presentation explores the challenges of selecting mechanical circulatory support devices in the context of cardiogenic shock, focusing on the limitations of randomized controlled trials and practical decision-making strategies. Gain valuable insights into the use of IABP, Impella, ECMO, and other devices to improve patient outcomes.
To watch the full-length session, click here.
